← All trials
NCT04639414
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Nov 20, 2020
- Last posted
- Nov 20, 2020
- Enrollment
- 192
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- The Deutsche Diabetes Forschungsgesellschaft e.V.Lead sponsor
- Novo NordiskCollaborator
- Boehringer IngelheimCollaborator
- Federal Ministry of Health, GermanyCollaborator
- The Deutsche Diabetes Forschungsgesellschaft e.V.Overall official - principal investigator
- German Center for Diabetes ResearchCollaborator
- Government of GermanyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.